WVE-006 Updated Oct 27
The next catalyst is the 600 mg monthly multidose cohort data from the RestorAATion-2 trial, expected in Q4 2026 (any day now). Positive data reinforcing the MZ-like phenotype and safety profile would support the registrational trial design and could drive the stock; disappointing results would raise questions about the accelerated approval timeline. The registrational trial itself has not yet started, so the path to market is still 2+ years away.
- WVE-006 is a first-in-class RNA editing therapy that corrects the root cause of AATD, addressing both lung and liver manifestations, no currently approved therapy does both.
- Phase 1b/2a RestorAATion-2 data showed achievement of the protective MZ-like phenotype with monthly subcutaneous dosing, with 71% reduction in toxic Z-AAT and 64% wild-type M-AAT.
- FDA aligned on a streamlined registrational pathway in October 2026: a single 2-year trial with a 1-year interim analysis that could support accelerated approval based on biomarkers, with no separate confirmatory study required.
- GSK returned full global rights to Wave in February 2026 after September 2025 data came below analyst expectations, a negative signal about the asset's commercial potential from a deep-pocketed partner.
- JP Morgan downgraded WVE to Neutral in September 2026, and several large holders (T. Rowe Price, Citadel, Federated Hermes) sharply trimmed or exited their positions in Q2 2026.
- The FDA required a new 2-year registrational trial rather than allowing the existing RestorAATion-2 data to support approval, meaning the path to market is longer and more expensive than some investors hoped.